Elanco Animal Health (ELAN) Amortization - Intangibles (2017 - 2026)
Elanco Animal Health (ELAN) reported Amortization - Intangibles of $138.0 million for Q1 2026, up 7.81% on a YoY basis from $128.0 million in Q1 2025, and down 0.72% sequentially from $139.0 million in Q4 2025.
Elanco Animal Health (ELAN) Amortization - Intangibles (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Amortization - Intangibles data on file, last reported at $138.0 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization - Intangibles rose 7.81% year-over-year to $138.0 million; the trailing twelve-month figure through Mar 2026 stood at $553.0 million (up 5.94% YoY), and the FY2025 full-year result was $543.0 million, up 3.04% from the prior year.
- Amortization - Intangibles retreated to $138.0 million in Q1 2026, from $139.0 million in the prior quarter.
- In the past five years, Amortization - Intangibles ranged from a high of $140.0 million in Q3 2023 to a low of $128.0 million in Q3 2022.
- A 5-year average of $134.4 million and a median of $134.0 million in 2023 frame the typical range for Amortization - Intangibles.
- Across the five-year window, Amortization - Intangibles dropped 9.22% in 2022 and increased 9.38% in 2023, its largest moves.
- Tracing ELAN's Amortization - Intangibles over 5 years: stood at $130.0 million in 2022, then climbed by 6.15% to $138.0 million in 2023, then slipped by 5.8% to $130.0 million in 2024, then gained by 6.92% to $139.0 million in 2025, then dropped by 0.72% to $138.0 million in 2026.
- Business Quant data shows ELAN's Amortization - Intangibles at $138.0 million in Q1 2026, $139.0 million in Q4 2025, and $140.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138.00 Mn |
| Dec 31, 2025 | 139.00 Mn |
| Sep 30, 2025 | 140.00 Mn |
| Jun 30, 2025 | 136.00 Mn |
| Mar 31, 2025 | 128.00 Mn |
| Dec 31, 2024 | 130.00 Mn |
| Sep 30, 2024 | 133.00 Mn |
| Jun 30, 2024 | 131.00 Mn |
| Mar 31, 2024 | 133.00 Mn |
| Dec 31, 2023 | 138.00 Mn |
| Sep 30, 2023 | 140.00 Mn |
| Jun 30, 2023 | 136.00 Mn |
| Mar 31, 2023 | 134.00 Mn |
| Dec 31, 2022 | 130.00 Mn |
| Sep 30, 2022 | 128.00 Mn |
| Jun 30, 2022 | 133.00 Mn |
| Mar 31, 2022 | 137.00 Mn |
| Dec 31, 2021 | 139.00 Mn |
| Sep 30, 2021 | 141.00 Mn |
| Jun 30, 2021 | 129.00 Mn |